Literature DB >> 21515083

[Predictive factors of tumour response after neoadjuvant chemoradiation for locally advanced rectal cancer and correlation of these factors with survival].

B Farnault1, L Moureau-Zabotto, C de Chaisemartin, B Esterni, B Lelong, F Viret, M Giovannini, G Monges, J-R Delpero, E Bories, O Turrini, P Viens, M Resbeut.   

Abstract

PURPOSE: Neoadjuvant chemoradiation followed by surgery is the standard of care for locally advanced rectal cancer. The aim of this study was to correlate tumour response to survival and to identify predictive factors for tumour response after chemoradiation. PATIENTS AND METHODS: From 1998 to 2008, 168 patients with histologically-proven locally advanced adenocarcinoma treated by preoperative chemoradiation before total mesorectal excision were retrospectively studied. They received a radiation dose of 45 Gy with a concomitant 5-fluoro-uracil-based chemotherapy. Analysis of tumour response was based on the lowering of T stage between pre-treatment endorectal ultrasound and pathologic specimens. Overall and progression-free survival was correlated with tumour response. Tumour response was analysed with predictive factors.
RESULTS: The median follow-up was 34 months. Five-year disease-free survival and overall survival were respectively of 44.4% and 74.5% in the whole population, 83.4% and 83.4% in patients with pathological complete response, 38.6% and 71.9% in patients with tumour downstaging, 29.1% and 58.9% in patients with absence of response. A pre-treatment concentration of carcinoembryonnic antigen below 5 ng/mL was significantly associated with tumour downstaging and significantly independently associated with pathologic complete tumour response (P = 0.019).
CONCLUSION: Downstaging and complete response after chemoradiation improved progression-free survival and overall survival of locally advanced rectal adenocarcinoma. In multivariate analysis, a pre-treatment concentration of carcinoembryonnic antigen below 5 ng/mL was associated with complete tumour response, hence with tumour downstaging.
Copyright © 2011 Société française de radiothérapie oncologique (SFRO). Published by Elsevier SAS. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21515083     DOI: 10.1016/j.canrad.2011.01.005

Source DB:  PubMed          Journal:  Cancer Radiother        ISSN: 1278-3218            Impact factor:   1.018


  5 in total

1.  Can serum dynamics of carcinoembryonic antigen level during neoadjuvant chemoradiotherapy in rectal cancer predict tumor response and recurrence? A multi-institutional retrospective study.

Authors:  Mi Joo Chung; Taek Keun Nam; Jae Uk Jeong; Sung Hwan Kim; Kyubo Kim; Hong Seok Jang; Bae Kwon Jeong; Jong Hoon Lee
Journal:  Int J Colorectal Dis       Date:  2016-07-28       Impact factor: 2.571

Review 2.  Risk factors for local recurrence following neoadjuvant chemoradiotherapy for rectal cancers.

Authors:  Jia-Yuan Peng; Zhong-Nan Li; Yu Wang
Journal:  World J Gastroenterol       Date:  2013-08-28       Impact factor: 5.742

3.  Prognostic significance of serum carcinoembryonic antigen normalization on survival in rectal cancer treated with preoperative chemoradiation.

Authors:  Mi-Joo Chung; Su-Mi Chung; Ji-Yoon Kim; Mi-Ryeong Ryu
Journal:  Cancer Res Treat       Date:  2013-09-30       Impact factor: 4.679

4.  Predictive value of carcinoembryonic antigen and carbohydrate antigen 19-9 related to downstaging to stage 0-I after neoadjuvant chemoradiotherapy in locally advanced rectal cancer.

Authors:  Jianyuan Song; Xiaoxue Huang; Zhuhong Chen; Mingqiu Chen; Qingliang Lin; Anchuan Li; Yuangui Chen; Benhua Xu
Journal:  Cancer Manag Res       Date:  2018-08-30       Impact factor: 3.989

5.  Predictive Response Value of Pre- and Postchemoradiotherapy Variables in Rectal Cancer: An Analysis of Histological Data.

Authors:  Marisa D Santos; Cristina Silva; Anabela Rocha; Carlos Nogueira; Eduarda Matos; Carlos Lopes
Journal:  Patholog Res Int       Date:  2016-01-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.